Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2017 Aug 18

PMID 28815480

Citations 27

Authors

Yu Yang

Xiaofeng Zhou

Shuangqing Gao

Hongbo Lin

Yanming Xie

Yuji Feng

Kui Huang

Siyan Zhan

Affiliations

Soon will be listed here.

Abstract

Introduction: Electronic healthcare databases (EHDs) are used increasingly for post-marketing drug safety surveillance and pharmacoepidemiology in Europe and North America. However, few studies have examined the potential of these data sources in China.

Methods: Three major types of EHDs in China (i.e., a regional community-based database, a national claims database, and an electronic medical records [EMR] database) were selected for evaluation. Forty core variables were derived based on the US Mini-Sentinel (MS) Common Data Model (CDM) as well as the data features in China that would be desirable to support drug safety surveillance. An email survey of these core variables and eight general questions as well as follow-up inquiries on additional variables was conducted. These 40 core variables across the three EHDs and all variables in each EHD along with those in the US MS CDM and Observational Medical Outcomes Partnership (OMOP) CDM were compared for availability and labeled based on specific standards.

Results: All of the EHDs' custodians confirmed their willingness to share their databases with academic institutions after appropriate approval was obtained. The regional community-based database contained 1.19 million people in 2015 with 85% of core variables. Resampled annually nationwide, the national claims database included 5.4 million people in 2014 with 55% of core variables, and the EMR database included 3 million inpatients from 60 hospitals in 2015 with 80% of core variables. Compared with MS CDM or OMOP CDM, the proportion of variables across the three EHDs available or able to be transformed/derived from the original sources are 24-83% or 45-73%, respectively.

Conclusions: These EHDs provide potential value to post-marketing drug safety surveillance and pharmacoepidemiology in China. Future research is warranted to assess the quality and completeness of these EHDs or additional data sources in China.

Citing Articles

Exploring willingness to use adverse drug reaction reporting systems: a multicentre qualitative study in China based on the technology acceptance model and task-technology fit integration approach.

Xia X, Yang X, Du J, Cheng W, Chen X, Zhang W BMJ Open. 2024; 14(10):e087701.

PMID: 39375182 PMC: 11459300. DOI: 10.1136/bmjopen-2024-087701.

Trends in admission rates of primary angle closure diseases for the urban population in China, 2011-2021.

Chen Q, Shen P, Zhou M, Cao Y, Zheng X, Zhao F Front Public Health. 2024; 12:1398674.

PMID: 38903596 PMC: 11188465. DOI: 10.3389/fpubh.2024.1398674.

Investigating Nonspecific Effects of the Live-Attenuated Japanese Encephalitis Vaccine on Lower Respiratory Tract Infections in Children Aged 25-35 Months: Retrospective Cohort Study.

Zhan S, Lin H, Yang Y, Chen T, Mao S, Fu C JMIR Public Health Surveill. 2024; 10:e53040.

PMID: 38498052 PMC: 10993859. DOI: 10.2196/53040.

Active Vaccine Safety Surveillance: Global Trends and Challenges in China.

Liu Z, Meng R, Yang Y, Li K, Yin Z, Ren J Health Data Sci. 2024; 2021:9851067.

PMID: 38487501 PMC: 10880162. DOI: 10.34133/2021/9851067.

Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018-2020.

Wu Q, Qian M, Welby S, Guignard A, Rosillon D, Gopala K Hum Vaccin Immunother. 2023; 19(3):2283912.

PMID: 38038626 PMC: 10732673. DOI: 10.1080/21645515.2023.2283912.

References

Zhao J, Henriksson A, Kvist M, Asker L, Bostrom H . Handling Temporality of Clinical Events for Drug Safety Surveillance. AMIA Annu Symp Proc. 2016; 2015:1371-80. PMC: 4765556. View

Zhang Y, Feng Y, Qu Z, Qi Y, Zhan S . Current situation and challenge of registry in China. Front Med. 2014; 8(3):294-9. DOI: 10.1007/s11684-014-0355-x. View

Wadman M . Experts call for active surveillance of drug safety. Nature. 2007; 446(7134):358-9. DOI: 10.1038/446358b. View

Behrman R, Benner J, Brown J, McClellan M, Woodcock J, Platt R . Developing the Sentinel System--a national resource for evidence development. N Engl J Med. 2011; 364(6):498-9. DOI: 10.1056/NEJMp1014427. View

Milea D, Azmi S, Reginald P, Verpillat P, Francois C . A review of accessibility of administrative healthcare databases in the Asia-Pacific region. J Mark Access Health Policy. 2016; 3. PMC: 4802693. DOI: 10.3402/jmahp.v3.28076. View

Xu Y, Zhou X, Suehs B, Hartzema A, Kahn M, Moride Y . A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance. Drug Saf. 2015; 38(8):749-65. DOI: 10.1007/s40264-015-0297-5. View

Sun Y, Gregersen H, Yuan W . Chinese health care system and clinical epidemiology. Clin Epidemiol. 2017; 9:167-178. PMC: 5360409. DOI: 10.2147/CLEP.S106258. View

Curtis L, Weiner M, Boudreau D, Cooper W, Daniel G, Nair V . Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012; 21 Suppl 1:23-31. DOI: 10.1002/pds.2336. View

Molokhia M, Tanna S, Bell D . Improving reporting of adverse drug reactions: Systematic review. Clin Epidemiol. 2010; 1:75-92. PMC: 2943157. DOI: 10.2147/clep.s4775. View

10.

Avorn J . Evaluating drug effects in the post-Vioxx world: there must be a better way. Circulation. 2006; 113(18):2173-6. DOI: 10.1161/CIRCULATIONAHA.106.625749. View

11.

Abbing-Karahagopian V, Kurz X, de Vries F, van Staa T, Alvarez Y, Hesse U . Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project. Curr Clin Pharmacol. 2013; 9(2):130-8. PMC: 4083447. DOI: 10.2174/1574884708666131111211802. View

12.

Platt R, Wilson M, Chan K, Benner J, Marchibroda J, McClellan M . The new Sentinel Network--improving the evidence of medical-product safety. N Engl J Med. 2009; 361(7):645-7. DOI: 10.1056/NEJMp0905338. View

13.

Lai E, Man K, Chaiyakunapruk N, Cheng C, Chien H, Chui C . Brief Report: Databases in the Asia-Pacific Region: The Potential for a Distributed Network Approach. Epidemiology. 2015; 26(6):815-20. DOI: 10.1097/EDE.0000000000000325. View

14.

Schneeweiss S, Rassen J, Glynn R, Myers J, Daniel G, Singer J . Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012; 12:180. PMC: 3533513. DOI: 10.1186/1471-2288-12-180. View

15.

Stephenson W, Hauben M . Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2006; 16(4):359-65. DOI: 10.1002/pds.1323. View

16.

Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C . An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Saf. 2013; 36(2):119-34. DOI: 10.1007/s40264-012-0009-3. View

17.

Wadman M . Strong medicine. Nat Med. 2005; 11(5):465-6. DOI: 10.1038/nm0505-465. View

18.

Platt R, Carnahan R, Brown J, Chrischilles E, Curtis L, Hennessy S . The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012; 21 Suppl 1:1-8. DOI: 10.1002/pds.2343. View

19.

Hu J, Xie Y, Shu Z, Yang W, Zhan S . Trends in the use of guideline-recommended medications and in-hospital mortality of patients with acute myocardial infarction in a Chinese population. PLoS One. 2015; 10(2):e0118777. PMC: 4338153. DOI: 10.1371/journal.pone.0118777. View

20.

Bourke A, Bate A, Sauer B, Brown J, Hall G . Evidence generation from healthcare databases: recommendations for managing change. Pharmacoepidemiol Drug Saf. 2016; 25(7):749-54. DOI: 10.1002/pds.4004. View